{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T05:24:35Z","timestamp":1794893075218,"version":"4.9.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"7867","license":[{"start":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T00:00:00Z","timestamp":1623801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T00:00:00Z","timestamp":1623801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2021,7,15]]},"DOI":"10.1038\/s41586-021-03642-9","type":"journal-article","created":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T12:08:14Z","timestamp":1623845294000},"page":"432-437","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":655,"title":["ctDNA guiding adjuvant immunotherapy in urothelial carcinoma"],"prefix":"10.1038","volume":"595","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7760-4724","authenticated-orcid":false,"given":"Thomas","family":"Powles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe June","family":"Assaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Davarpanah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Banchereau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadett E.","family":"Szabados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kobe C.","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Grivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Oudard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen E.","family":"Gschwend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Albers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siamak","family":"Daneshmand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard G.","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himanshu","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey","family":"Aleshin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Perdicchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingbin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Shames","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viraj","family":"Degaonkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Bais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2328-3421","authenticated-orcid":false,"given":"Joaquim","family":"Bellmunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Mariathasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,16]]},"reference":[{"key":"3642_CR1","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s40291-019-00390-5","volume":"23","author":"RI Chin","year":"2019","unstructured":"Chin, R. I. et al. Detection of solid tumor molecular residual disease\u00a0(MRD) using circulating tumor DNA (ctDNA). Mol. Diagn. Ther. 23, 311\u2013331 (2019).","journal-title":"Mol. Diagn. Ther."},{"key":"3642_CR2","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1200\/JCO.18.02052","volume":"37","author":"E Christensen","year":"2019","unstructured":"Christensen, E. et al. Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. J. Clin. Oncol. 37, 1547\u20131557 (2019).","journal-title":"J. Clin. Oncol."},{"key":"3642_CR3","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature22364","volume":"545","author":"C Abbosh","year":"2017","unstructured":"Abbosh, C. et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature 545, 446\u2013451 (2017).","journal-title":"Nature"},{"key":"3642_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-11291-0","volume":"7","author":"MBH Thomsen","year":"2017","unstructured":"Thomsen, M. B. H. et al. Comprehensive multiregional analysis of molecular heterogeneity in bladder cancer. Sci. Rep. 7, 11702 (2017).","journal-title":"Sci. Rep."},{"key":"3642_CR5","doi-asserted-by":"publisher","first-page":"6909","DOI":"10.1158\/1078-0432.CCR-18-2688","volume":"25","author":"A Snyder","year":"2019","unstructured":"Snyder, A., Morrissey, M. P. & Hellmann, M. D. Use of circulating tumor DNA for cancer immunotherapy. Clin. Cancer Res. 25, 6909\u20136915 (2019).","journal-title":"Clin. Cancer Res."},{"key":"3642_CR6","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1056\/NEJMra1706174","volume":"379","author":"RB Corcoran","year":"2018","unstructured":"Corcoran, R. B. & Chabner, B. A. Application of cell-free DNA analysis to cancer treatment. N. Engl. J. Med. 379, 1754\u20131765 (2018).","journal-title":"N. Engl. J. Med."},{"key":"3642_CR7","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/S1470-2045(20)30444-7","volume":"21","author":"NC Turner","year":"2020","unstructured":"Turner, N. C. et al. Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. Lancet Oncol. 21, 1296\u20131308 (2020).","journal-title":"Lancet Oncol."},{"key":"3642_CR8","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1038\/s41591-020-0933-1","volume":"26","author":"PV Nuzzo","year":"2020","unstructured":"Nuzzo, P. V. et al. Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes. Nat. Med. 26, 1041\u20131043 (2020).","journal-title":"Nat. Med."},{"key":"3642_CR9","doi-asserted-by":"publisher","first-page":"346ra92","DOI":"10.1126\/scitranslmed.aaf6219","volume":"8","author":"J Tie","year":"2016","unstructured":"Tie, J. et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci. Transl. Med. 8, 346ra92 (2016).","journal-title":"Sci. Transl. Med."},{"key":"3642_CR10","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1001\/jamaoncol.2019.1838","volume":"5","author":"I Garcia-Murillas","year":"2019","unstructured":"Garcia-Murillas, I. et al. Assessment of molecular relapse detection in early-stage breast cancer. JAMA Oncol. 5, 1473\u20131478 (2019).","journal-title":"JAMA Oncol."},{"key":"3642_CR11","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/s43018-020-0096-5","volume":"1","author":"SV Bratman","year":"2020","unstructured":"Bratman, S. V. et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nat. Cancer 1, 873\u2013881 (2020).","journal-title":"Nat. Cancer"},{"key":"3642_CR12","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.cell.2020.09.001","volume":"183","author":"BY Nabet","year":"2020","unstructured":"Nabet, B. Y. et al. Noninvasive early identification of therapeutic benefit from immune checkpoint inhibition. Cell 183, 363\u2013376.e13 (2020).","journal-title":"Cell"},{"key":"3642_CR13","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1158\/2159-8290.CD-20-0047","volume":"10","author":"Q Zhang","year":"2020","unstructured":"Zhang, Q. et al. Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade. Cancer Discov. 10, 1842\u20131853 (2020).","journal-title":"Cancer Discov."},{"key":"3642_CR14","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1200\/JCO.2018.77.7847","volume":"36","author":"ATC Chan","year":"2018","unstructured":"Chan, A. T. C. et al. Analysis of plasma Epstein\u2013Barr virus DNA in nasopharyngeal cancer after chemoradiation to identify high-risk patients for adjuvant chemotherapy: a randomized controlled trial. J. Clin. Oncol. 36, 3091\u20133100 (2018).","journal-title":"J. Clin. Oncol."},{"key":"3642_CR15","doi-asserted-by":"publisher","first-page":"v867","DOI":"10.1093\/annonc\/mdz394.019","volume":"30","author":"J Taieb","year":"2019","unstructured":"Taieb, J. et al. Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: prognostic and predictive value for adjuvant treatment duration. Ann. Oncol. 30, v867 (2019).","journal-title":"Ann. Oncol."},{"key":"3642_CR16","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","volume":"22","author":"J Bellmunt","year":"2021","unstructured":"Bellmunt, J. et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 22, 525\u2013537 (2021).","journal-title":"Lancet Oncol."},{"key":"3642_CR17","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","volume":"19","author":"JP Stein","year":"2001","unstructured":"Stein, J. P. et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol. 19, 666\u2013675 (2001).","journal-title":"J. Clin. Oncol."},{"key":"3642_CR18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","volume":"389","author":"AV Balar","year":"2017","unstructured":"Balar, A. V. et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389, 67\u201376 (2017).","journal-title":"Lancet"},{"key":"3642_CR19","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909\u20131920 (2016).","journal-title":"Lancet"},{"key":"3642_CR20","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn, L. et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N. Engl. J. Med. 379, 2220\u20132229 (2018).","journal-title":"N. Engl. J. Med."},{"key":"3642_CR21","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","volume":"391","author":"T Powles","year":"2018","unstructured":"Powles, T. et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 391, 748\u2013757 (2018).","journal-title":"Lancet"},{"key":"3642_CR22","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","volume":"25","author":"T Powles","year":"2019","unstructured":"Powles, T. et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat. Med. 25, 1706\u20131714 (2019).","journal-title":"Nat. Med."},{"key":"3642_CR23","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","volume":"378","author":"MD Hellmann","year":"2018","unstructured":"Hellmann, M. D. et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N. Engl. J. Med. 378, 2093\u20132104 (2018).","journal-title":"N. Engl. J. Med."},{"key":"3642_CR24","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan, S. et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544\u2013548 (2018).","journal-title":"Nature"},{"key":"3642_CR25","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson, A. G. et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171, 540\u2013556.e25 (2017).","journal-title":"Cell"},{"key":"3642_CR26","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1200\/JCO.2021.39.6_suppl.391","volume":"39","author":"DF Bajorin","year":"2021","unstructured":"Bajorin, D. F. et al. First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC). J. Clin. Oncol. 39, 391 (2021).","journal-title":"J. Clin. Oncol."},{"key":"3642_CR27","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1093\/annonc\/mdz048","volume":"30","author":"L Tan","year":"2019","unstructured":"Tan, L. et al. Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA. Ann. Oncol. 30, 804\u2013814 (2019).","journal-title":"Ann. Oncol."},{"key":"3642_CR28","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamaoncol.2019.0528","volume":"5","author":"T Reinert","year":"2019","unstructured":"Reinert, T. et al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA Oncol. 5, 1124\u20131131 (2019).","journal-title":"JAMA Oncol."},{"key":"3642_CR29","doi-asserted-by":"publisher","first-page":"4255","DOI":"10.1158\/1078-0432.CCR-18-3663","volume":"25","author":"RC Coombes","year":"2019","unstructured":"Coombes, R. C. et al. Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence. Clin. Cancer Res. 25, 4255\u20134263 (2019).","journal-title":"Clin. Cancer Res."},{"key":"3642_CR30","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1093\/bioinformatics\/btq057","volume":"26","author":"TD Wu","year":"2010","unstructured":"Wu, T. D. & Nacu, S. Fast and SNP-tolerant detection of complex variants and splicing in short reads. Bioinformatics 26, 873\u2013881 (2010).","journal-title":"Bioinformatics"},{"key":"3642_CR31","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/978-1-4939-3578-9_15","volume":"1418","author":"TD Wu","year":"2016","unstructured":"Wu, T. D., Reeder, J., Lawrence, M., Becker, G. & Brauer, M. J. GMAP and GSNAP for genomic sequence alignment: enhancements to speed, accuracy, and functionality. Methods Mol. Biol. 1418, 283\u2013334 (2016).","journal-title":"Methods Mol. Biol."},{"key":"3642_CR32","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.1093\/nar\/gks461","volume":"40","author":"D Wu","year":"2012","unstructured":"Wu, D. & Smyth, G. K. Camera: a competitive gene set test accounting for inter-gene correlation. Nucleic Acids Res. 40, e133 (2012).","journal-title":"Nucleic Acids Res."},{"key":"3642_CR33","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41586-021-03642-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41586-021-03642-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41586-021-03642-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T18:10:47Z","timestamp":1684606247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-021-03642-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,16]]},"references-count":33,"journal-issue":{"issue":"7867","published-print":{"date-parts":[[2021,7,15]]}},"alternative-id":["3642"],"URL":"https:\/\/doi.org\/10.1038\/s41586-021-03642-9","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,16]]},"assertion":[{"value":"8 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.P. received honoraria from advisory\/consultancy roles with AstraZeneca, BMS, Exelixis, Incyte, Ipsen, Merck, MSD, Novartis, Pfizer, Seattle Genetics, Merck Serono (EMD Serono), Astellas, Johnson & Johnson, Eisai and Roche; institutional research funding support from AstraZeneca, Roche, BMS, Exelixis, Ipsen, Merck, MSD, Novartis, Pfizer, Seattle Genetics, Merck Serono (EMD Serono), Astellas and Johnson & Johnson; and travel, accommodation and expenses support from Roche, Pfizer, MSD, AstraZeneca and Ipsen. Z.J.A. discloses employment with Genentech, previous employment with Natera and stock and other ownership interests with Roche. N.D., D.S.S., V.D. and K.C.Y. disclose employment with Genentech and stock and other ownership interests with Roche. R.B. and X.S. disclose employment with and own stock or other ownership interests in Genentech. B.E.S. discloses honoraria from Merck, Roche, Pfizer and Ellipses; advisory\/consulting fees from Merck, Ellipses and Onc; expert testimony or speakers\u2019 bureau fees from Merck and Pfizer; travel, accommodation or expenses support from Roche and Pfizer. P.G. received consulting fees from AstraZeneca, Bayer, BMS, Clovis Oncology, Driver, Dyania Health, EMD Serono, Exelixis, Foundation Medicine, GlaxoSmithKline, Genentech, Genzyme, Heron Therapeutics, Immunomedics, Janssen, Merck, Mirati Therapeutics, Pfizer, Roche, Seattle Genetics and QED Therapeutics; and institutional research funding support from AstraZeneca, Bavarian Nordic, Bayer, BMS, Clovis Oncology, Debiopharm, Genentech, GlaxoSmithKline, Immunomedics, Kure It Cancer Research, Merck, Mirati Therapeutics, OncogeneX, Pfizer and QED Therapeutics. M.H. received honoraria or advisory fees from Pfizer, AstraZeneca, Bayer, Genentech, PER, Projects in Knowledge, Astellas Pharma, Sanofi\/Genzyme, Research to Practice, BMS and Daiichi Sankyo; research funding support from AstraZeneca, Genentech, Pfizer and Bayer; and travel, accommodation or expenses support from Pfizer, Bayer, Astellas Pharma and Genentech\/Roche; and also has two pending patents and one licensed patent with Imbio. S.O. received advisory\/consulting fees and honorarium from Astellas, Bayer, BMS, Eisai, Janssen, MSD, Novartis, Pfizer and Sanofi; research funding support from Ipsen and Sanofi; and travel, accommodation or expenses support from Bayer, BMS, Eisai, MSD, Novartis and Pfizer. J.E.G. received consulting fees or honoraria from Amgen, AstraZeneca, Bayer, Janssen-Cilag, Merck, MSD, Pfizer, Roche and BMS. P.A. received advisory\/consulting fees and honoraria from MSD Oncology, Sanofi and Roche\/Genentech. D.C. received consulting fees from Astellas Pharma, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Ipsen, Janssen Oncology, Lilly, MSD Oncology, Novartis, Pfizer, Pierre Fabre, Roche\/Genentech and Sanofi; research funding support from Janssen Oncology; and travel, accommodation or expenses support from AstraZeneca Spain, BMS, Pfizer and Roche. H.N. received research funding support from Ono and Chugai; consulting fees from Bayer, Chugai, BMS, Astellas, MSD, Janssen and AstraZeneca; and participated in speakers\u2019\u00a0bureaus for Chugai, MSD, Astellas and AstraZeneca. S.D. received honoraria from Ferring, Olympus, Pacific Edge, Photocure, QED, MDxHealth and Spectrum Pharmaceuticals; advisory fees from Ferring, Photocure, QED and Taris; and research funding, travel, accommodation or expenses support from Photocure. S.S., H.S. and A.A disclose employment with Natera. B.G.Z. discloses employment with and owns stock or other ownership interests in Natera. M.P. discloses employment with F. Hoffmann-La Roche. J.Z. discloses employment with Hoffmann-La Roche. C.C., C.B. and S.M. disclose employment with Genentech. J.B. received advisory\/consulting fees from Astellas Pharma, AstraZeneca\/MedImmune, BMS, Genentech, Merck, Novartis, Pfizer and Pierre Fabre; honoraria from UpToDate; research funding support from Millennium, Sanofi and Pfizer\/EMD Serono; owns stock or other ownership interests in Rainer; and travel, accommodation or expenses support from Pfizer, MSD Oncology and Ipsen.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}